| 纯度 | >95 % HPLC. |
| 种属 | Human |
| 靶点 | CD14 |
| Uniprot No | P08571 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 20-352aa |
| 氨基酸序列 | TTPEPCELDDEDFRCVCNFSEPQPDWSEAFQCVSAVEVEIHAGGLNLEPF LKRVDADADPRQYADTVKALRVRRLTVGAAQVPAQLLVGALRVLAYSRLK ELTLEDLKITGTMPPLPLEATGLALSSLRLRNVSWATGRSWLAELQQWLK PGLKVLSIAQAHSPAFSCEQVRAFPALTSLDLSDNPGLGERGLMAALCPH KFPAIQNLALRNTGMETPTGVCAALAAAGVQPHSLDLSHNSLRATVNPSA PRCMWSSALNSLNLSFAGLEQVPKGLPAKLRVLDLSCNRLNRAPQPDELP EVDNLTLDGNPFLVPGTALPHEGSMNSGVVPAC |
| 预测分子量 | 36 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CD14重组蛋白的3篇代表性文献及其摘要概括：
1. **文献名称**: *Recombinant soluble CD14 mediates the activation of endothelial cells by lipopolysaccharide*
**作者**: **Frey EA**, et al.
**摘要**: 该研究探讨了重组可溶性CD14(sCD14)在脂多糖(LPS)诱导的内皮细胞活化中的作用，证明sCD14通过增强LPS与内皮细胞的结合，促进炎症因子(如IL-6和ICAM-1)的表达，揭示了其在系统性炎症反应中的关键调控机制。
2. **文献名称**: *Structural basis of CD14-dependent TLR4 recognition of bacterial LPS*
**作者**: **Kim JI**, et al.
**摘要**: 通过X射线晶体学解析了CD14与LPS复合物的三维结构，阐明CD14通过疏水腔结合LPS分子，并将LPS传递给TLR4-MD2受体复合物，从而激活先天免疫信号通路，为靶向CD14的抗炎药物设计提供结构基础。
3. **文献名称**: *Soluble CD14 acts as a DAMP in human sepsis by promoting inflammation and organ injury*
**作者**: **Andrade VB**, et al.
**摘要**: 研究发现脓毒症患者血浆中sCD14水平显著升高，并通过体外实验证明重组sCD14可直接激活单核细胞释放促炎细胞因子(如TNF-α和IL-1β)，提示sCD14不仅是LPS的传递蛋白，还可作为损伤相关分子模式(DAMP)加剧炎症反应。
4. **文献名称**: *Recombinant CD14 prevents mortality in mice with Pseudomonas aeruginosa sepsis*
**作者**: **Haziot A**, et al.
**摘要**: 在小鼠铜绿假单胞菌败血症模型中，外源性重组CD14显著降低死亡率，其机制与中和LPS毒性、减少促炎因子风暴及改善免疫细胞功能有关，表明sCD14在抗感染治疗中的潜在应用价值。
以上文献涵盖CD14在炎症信号传导、结构机制、疾病模型及治疗干预中的研究，均为该领域的经典或前沿成果。
CD14 is a glycoprotein that serves as a pattern recognition receptor (PRR) prominently expressed on myeloid cells, such as monocytes and macrophages, and plays a critical role in innate immunity. It binds to pathogen-associated molecular patterns (PAMPs), particularly bacterial lipopolysaccharide (LPS), and facilitates the activation of Toll-like receptor 4 (TLR4)/MD-2 signaling pathways, triggering pro-inflammatory cytokine production. CD14 exists in two forms: membrane-bound (mCD14) anchored via a glycosylphosphatidylinositol (GPI) tail and soluble (sCD14) circulating in plasma, both involved in LPS detection and immune regulation. Its leucine-rich repeat (LRR) domains mediate interactions with microbial components and host proteins.
Recombinant CD14 proteins are engineered using expression systems (e.g., mammalian or bacterial cells) to study its structure-function relationships or therapeutic potential. These proteins retain key functional epitopes, enabling research into LPS signaling mechanisms, TLR4 pathway modulation, and drug screening. Recombinant sCD14 is particularly valuable for in vitro studies, as it mimics the natural soluble form’s ability to transfer LPS to TLR4/MD-2 on cells lacking mCD14. Applications extend to sepsis, autoimmune diseases, and chronic inflammatory conditions, where dysregulated CD14 signaling contributes to pathogenesis. For instance, recombinant CD14 may help neutralize excessive LPS or serve as a tool to develop anti-inflammatory therapies.
In diagnostics, recombinant CD14 aids in detecting endotoxin contamination in pharmaceuticals or clinical samples. However, challenges persist in maintaining its native conformation and post-translational modifications (e.g., glycosylation) during production, which influence ligand-binding efficiency. Despite this, recombinant CD14 remains indispensable for advancing immune response research and therapeutic innovation.
×
